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Abstract
Background: There is an increasing amount of reports on IFITM1 (interferon-inducible transmembrane protein 1) in
various malignancies. The aim of this study was to examine the expression of IFITM1 and its prognostic significance
in gastroesophageal adenocarcinoma.
Methods: Tissue samples were obtained from a consecutive cohort of 174 patients surgically treated between 2006
and 2010 for gastroesophageal (gastric, gastroesophageal junction and esophageal) adenocarcinoma, not subjected to
neoadjuvant therapy. Expression of IFITM1 was examined using immunohistochemistry on tissue microarrays of
primary tumors and paired samples of adjacent normal epithelium, intestinal metaplasia and lymph node metastases.
Results: Expression of IFITM1 was significantly elevated in primary tumors and lymph node metastases compared to
adjacent normal epithelium and intestinal metaplasia, regardless of tumor location. Overexpression of IFITM1 was
associated with M0-disease (no distant metastases). In gastric cancer IFITM1 expression was significantly associated with
improved TTR (time to recurrence) in Kaplan-Meier analysis and Cox regression, both in the unadjusted analysis (HR
0.33, 95 % CI 0.12-0.88) and in the adjusted analysis (HR 0.32, 95 % CI 0.12-0.87) but there was no significant impact on
OS (overall survival). In esophageal adenocarcinoma expression of IFITM1 had no impact on TTR or OS in Kaplan-Meier-
analyses, but in the adjusted Cox regression IFITM1 expression had a negative impact on both TTR (HR 3.05, 95 % CI
1.09-8.53) and OS (HR 2.71, 95 % CI 1.11-6.67).
Conclusions: IFITM1 was overexpressed in gastroesophageal adenocarcinoma and associated with M0-disease. In
gastric cancer IFITM1 expression had a positive impact on TTR but in esophageal cancer it seemed to have an adverse
impact on survival.
The reason for the diverging prognostic impact of IFITM1 in esophageal and gastric cancer is unclear and warrants
further studies.
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Background
Gastroesophageal adenocarcinoma is the 5th most com-
mon cancer worldwide [1]. The incidence of esophageal
and GE (gastroesophageal) junction adenocarcinoma has
drastically increased in many Western countries for the
last four decades [2, 3]. Suggested factors to explain this
increase are gastroesophageal reflux disease, obesity and
decreased prevalence of Helicobacter pylori infection
[4, 5]. In contrast, the incidence of gastric adenocarcinoma
has declined globally for several decades [6], possibly due to
decreased prevalence of Helicobacter pylori infection and
improved dietary conditions [7].
The prognosis of gastroesophageal adenocarcinoma
is generally poor, at least in Western populations. For
operable patients with resectable tumors recent studies
have shown that the addition of neoadjuvant and/or
adjuvant chemotherapy or chemoradiotherapy improves
the 5-year survival rate with 10–15 % [8–11]. To fur-
ther improve the overall survival in gastroesophageal
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adenocarcinoma, a deepened understanding of the tumor
biology is required. Moreover, identification of prognostic
and response predictive biomarkers is warranted to
optimize and personalize the treatment strategies.
IFITM1 (interferon-inducible transmembrane protein 1),
also known as 9–27, Leu-13 or CD225, is a cell surface
17-kDa membrane protein that is encoded on the short
arm of chromosome 11. It is mainly known as an inhibitor
of viral entry and replication [12], but it has also
been associated with angiogenesis [13], inflammatory
bowel disease [14] and osteogenesis [15].
There are now emerging data on IFITM1 and its role
in malignancy. An upregulation of IFITM1 in different
types of cancer and promotion of tumorigenesis by en-
hancing tumor cell migration, invasion and proliferation
has been reported in several studies [16–23] but the op-
posite has also been shown [24–26]. Overexpression of
IFITM1 has been reported to correlate with improved
survival in glioma and chronic myeloid leukemia [17, 27]
but in a South Korean study on gastric cancer, there was
a trend towards worse survival in patients with high expres-
sion of IFITM1 [23]. Apart from the latter study, the know-
ledge on IFITM1 in gastroesophageal cancer survival is
very limited, especially in Western populations. Therefore,
the current study was designed to explore the expression
and prognostic significance of IFITM1 in adenocarcinoma
of the esophagus, GE junction and stomach in a consecu-
tive cohort of patients from southern Sweden, that were
treated 2006–2010, prior to the wide implementation of
(neo-)adjuvant oncological treatment.
Methods
Study design and participants
The study comprises a consecutive cohort of 174 pa-
tients with chemo-/radiotherapy-naive gastroesophageal
(gastric, GE junction and esophageal) adenocarcinoma
subjected to surgical resection at the University Hospi-
tals of Lund and Malmö between January 1, 2006 and
December 31, 2010. This patient cohort has been used
in several previous reports on other biomarkers [28–32].
Data on survival and recurrence were updated until De-
cember 31 2014. Tumor location was based on endos-
copy findings. Classification of tumor stage was done
according to UICC/AJCC TNM edition 7. Residual
Table 1 Patient and tumor characteristics
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tumor status was classified as: R0 = no residual tumor,
R1 =microscopic residual tumor, R2 =macroscopic
residual tumor. The vast majority of the patients were
operated on with a curative intent but three patients
with metastatic disease were resected to palliate symptoms
from the primary tumor. In 16 patients, M1-disease
(distant metastases) was revealed either during surgery or
in the resected specimens. All patients had surgery
up-front, without neoadjuvant oncological therapy and
a minority (7.5 %) of the patients received adjuvant
treatment (chemo-/radiotherapy). Clinical data, recur-
rence status and vital status were obtained retrospectively
from medical records. Clinicopathological data and fol-
low-up data are described in Table 1. The study was
approved by the regional ethics committee at Lund Uni-
versity (ref nr 445/07).
Tissue microarrays
Using a semi-automated arraying device (TMArrayer™,
Pathology Devices, Westminster, MD, USA) tissue
microarrays (TMAs) were constructed. From all 174
primary tumors duplicate cores (1 mm) were obtained
from areas with morphologically viable cancer in different
blocks. In 81 cases lymph node metastases were sampled
Table 2 Associations of IFITM1 expression in primary tumors with clinicopathological data
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in duplicate cores. In addition 1–3 cores from intestinal
metaplasia (gastric intestinal metaplasia or Barrett’s
esophagus) were sampled in 73 cases. Single core samples
from adjacent normal gastric mucosa (131 cases) and nor-
mal squamous epithelium of the esophagus (96 cases)
were also retrieved. All samples were paired.
Immunohistochemistry
For immunohistochemical analysis of IFITM1 expression,
4 μm TMA-sections were automatically pre-treated using
the PT Link system and then stained in an Autostainer
Plus (DAKO; Glostrup, Copenhagen, Denmark) with the
rabbit polyclonal anti-IFITM1 antibody HPA004810
(Atlas Antibodies AB, Stockholm, Sweden) diluted 1:250.
The specificity of the antibody has been validated [33].
Staining was assessed by two different observers (DB
and AG) blinded to clinical and outcome data. Scoring
discrepancies were discussed to reach consensus. IFITM1
staining was mainly detected in the cytoplasm, with
an accentuation towards the membrane. The fraction
of stained tumor cells was scored as: 0 (0–1 %), 1
(2–25 %), 2 (26–50 %), 3 (51–75 %) or 4 (>75 %).
Staining intensity was scored as: 0 (negative), 1 (weak), 2
(moderate) or 3 (strong). By multiplying fraction and in-
tensity a combined score (0–12) was constructed.
Statistical analysis
The Mann–Whitney U test was applied to compare the
distribution of IFITM1 expression in different tissues (Fig. 2)
and also to describe the relationship between IFITM1
expression and clinicopathological factors (Table 2). Time
to recurrence (TTR) was defined as time from date of
surgery to date of biopsy or radiology proven recurrent
disease. Overall survival (OS) was defined as time from date
of surgery to date of death. TTR and OS were analysed for
resected M0-patients with no macroscopic residual tumor
Table 3 Hazard ratios for recurrence and death M0 R0-1
Time to recurrence
Unadjusted Adjusteda






































































aAdjusted for: T-stage, N-stage, R-classification
bAdjusted for: age, T-stage, N-stage, R-classification, differentiation grade
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(R0-1). To determine the optimal prognostic cut-off for
IFITM1 expression in the primary tumors, ROC-curves
were used. Differences in Kaplan-Meier survival curves
were calculated by log-rank test (Fig. 3). Unadjusted
and adjusted hazard ratios for survival were determined
using Cox proportional-hazards regression (Table 3). The
adjusted model for TTR included T-stage, N-stage and R-
classification. For OS, the adjusted model included age, T-
stage, N-stage, R-classification and differentiation grade.
All tests were 2-sided and a p-value <0.05 was considered
significant. IBM® SPSS® Statistics version 22.0.0.1 for Mac
was used for all statistical analyses.
Results
Expression of IFITM1 in normal epithelium, intestinal
metaplasia, primary tumors and lymph node metastases
Immunohistochemical expression of IFITM1 could be
assessed in 91/96 (95 %) samples with esophageal
squamous epithelium, 122/131 (93 %) samples with
gastric mucosa, 56/73 (77 %) samples with intestinal
metaplasia (gastric intestinal metaplasia or Barrett’s
esophagus), 169/174 (97 %) samples with primary tumors,
and 77/81 (95 %) samples with lymph node metastases.
Sample images are shown in Fig. 1. The distribution of im-
munohistochemical expression of IFITM1 in the different
tissue types is shown in Fig. 2. Expression of IFITM1 was
significantly elevated in primary tumors and lymph node
metastases compared to adjacent normal epithelium and
intestinal metaplasia (Fig. 2). There were no significant
differences of IFITM1 expression in primary tumors
grouped by tumor location (Table 2).
Associations of IFITM1 expression in primary tumors with
clinicopathological data
Table 2 describes the expression of IFITM1 in primary
tumors in relationship to clinicopathological data for the
entire cohort and for the separate tumor locations. In
the entire cohort, IFITM1 was significantly elevated in
Fig. 1 Sample immunohistochemical images of IFITM1 staining in gastroesophageal adenocarcinoma primary tumors with (a) negative, (b) weak,
(c) moderate, and (d) strong staining of tumor cells. Magnification x 20
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M0-disease, most notably in gastric cancer. There was a
trend towards higher IFITM1 expression in primary tu-
mors with a background of intestinal metaplasia. In the
subset of gastric tumors there were significant associa-
tions of high IFITM1 expression with age and Lauren’s
intestinal type, respectively.
Impact of IFITM1 expression on survival
Survival analyses were performed on patients with M0-
disease and no macroscopic residual tumor (R0-1). Using
ROC-curves, both for the separate primary tumor loca-
tions and for the entire cohort and with regard to TTR as
well as OS, an optimal cut-off at 3 (IFITM1 low < 3,
IFITM1 high 3–12) was identified and subsequently used
for both TTR and OS, irrespectively of tumor location. In
esophageal adenocarcinoma, expression of IFITM1 had
no impact on TTR and OS in the Kaplan-Meier-analyses
(Fig. 3a, d), but in the adjusted Cox regression analyses
(Table 3 and Additional file 1: Table S1)) high IFITM1 ex-
pression had a negative impact on both TTR (HR 3.05,
95 % CI 1.09-8.53, p = 0.034) and OS (HR 2.71, 95 % CI
1.11-6.67, p = 0.029). IFITM1 expression in GE junction
tumors did not correlate with TTR or OS in neither
Kaplan-Meier (Fig. 3b, e) nor Cox regression analyses
(Table 3 and Additional file 1: Table S2). In gastric cancer,
high IFITM1 expression was significantly associated with
improved TTR in the Kaplan-Meier analyses (Fig. 3c, f )
and Cox regression (Table 3 and Additional file 1:
Table S3), both in the unadjusted analysis (HR 0.33, 95 %
CI 0.12-0.88, p = 0.026) and in the adjusted analysis
(HR 0.32, 95 % CI 0.12-0.87, p = 0.026) but there was
no significant impact on OS.
Of note, considering the association of high IFITM1
with Lauren’s intestinal type in gastric cancer (Table 2),
we also tested to replace IFITM1 with Lauren classifica-
tion in the adjusted Cox regression model but the hazard
ratio of Lauren classification for TTR was not significant
(data not shown) and when we added Lauren classification
to the model with IFITM1 the hazard ratio of IFITM1 on
TTR remained significant (data not shown). Thus, we do
not believe that IFITM1 is just a marker for Lauren’s in-
testinal type.
Of the 78 patients that developed recurrent disease dur-
ing the follow-up period, 36 patients received palliative
treatment with chemotherapy and/or radiotherapy. To
what extent palliative therapy may have affected the out-
come is unclear, but due to a considerable heterogeneity re-
garding treatment type, doses and duration as well as to
avoid selection bias (patients offered active palliative treat-
ment usually have better performance status and prognosis)
we decided not to include palliative oncological treatment
after recurrence as a variable in the survival analyses.
Discussion
The current study showed a significantly increased ex-
pression of IFITM1 in gastroesophageal adenocarcinoma
Fig. 2 Box plots visualizing the distribution of immunohistochemical IFITM1 expression (fraction x intensity) in normal squamous epithelium, normal
gastric mucosa, intestinal metaplasia (Barrett’s esophagus or gastric intestinal metaplasia), primary tumors and lymph node metastases in the entire
cohort. The whiskers represent the largest values within 1.5 x interquartile range, the circles and asterisks represent outliers and extremes, respectively
Borg et al. Biomarker Research  (2016) 4:10 Page 6 of 9
compared to adjacent normal epithelium. This finding is
in accordance with other reports on IFITM1 in gastric
and colorectal adenocarcinoma [23, 34, 35]. The associ-
ation of high IFITM1 expression and M0-disease, par-
ticularly seen in gastric cancer, has to our knowledge not
been described previously.
In gastric cancer with high expression of IFITM1, we
have demonstrated consistent findings of a beneficial ef-
fect on TTR. However, we could not demonstrate any
significant relationship between IFITM1 and OS in gas-
tric cancer, and one possible explanation for this could
be the older age in these patients. It has previously been
suggested that IFITM1 may have an adverse impact on
OS in gastric cancer [23] but, even though our data on
OS were non-significant, the association of elevated
IFITM1 with M0-disease and the favorable impact on
TTR implies that high expression of IFITM1 could ra-
ther be a positive prognostic factor in gastric cancer. It
may seem like a paradox that the overexpression of
IFITM1 in gastric cancer, which in other malignancies
has been shown to promote tumorigenesis, was associ-
ated with M0-disease and a favorable TTR. A possible
explanation might be that gastric tumorigenesis associ-
ated with elevated IFITM1 confers a less malignant
phenotype. Support for this is the observed association
of high IFITM1 expression and the prognostically favor-
able Lauren’s intestinal type demonstrated both in this
study and by others [23]. A similar contradiction has
been described in glioma cells where knockdown of
IFITM1 was demonstrated to inhibit proliferation, mi-
gration and invasion [17, 18], whereas reduced expres-
sion of IFITM1 correlated with shorter survival in a
cohort of 30 glioma patients [17].
The proposed negative impact of IFITM1 on TTR and
OS in esophageal adenocarcinoma has to be interpreted
with caution since it was only demonstrated in the ad-
justed Cox regression analysis. However, if true, this
would suggest the involvement of a different tumori-
genic pathway than in gastric cancer. Esophageal and
gastric cancers are indeed different malignancies, with
diverging incidence trends and different risk factors. For
instance, Helicobacter pylori infection is associated with
gastric cancer [7] but may be a protective factor for
esophageal cancer [5].
The exact function of IFITM1 in malignancy is poorly
understood and its role might differ depending on tumor
cell type and context. IFITM1 has been demonstrated to
promote malignant progression in gastric cancer cells by
Fig. 3 Kaplan-Meier plots of time to recurrence and overall survival according to IFITM1 expression in patients with M0-disease and no macroscopic
residual tumor (R0-1). Time to recurrence in a esophageal cancer, b GE junction cancer, and c gastric cancer. Overall survival in d esophageal cancer,
e GE junction cancer, and f gastric cancer
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increasing invasion and migration and by suppressing
natural killer cell activity [23, 35]. It has been shown that
IFITM1 expression is regulated by DNA methylation of
its promoter region [23]. Furthermore, expression of a
transcript of CDH1 (E-cadherin) intron 2 (CDH1a) has
been shown to increase gastric cancer cell invasion and
angiogenesis and this increase correlated with IFITM1
expression [36]. The downstream effectors of IFITM1 on
tumorigenesis are largely unknown but one possible
mechanism of promoting invasion could be the upregu-
lation of matrix metalloproteinases [20].
An association between high IFITM1 expression and
sensitivity to cisplatin has been described in esophageal
squamous cell carcinoma [37] whereas in gastric cancer,
overexpression of IFITM1 may confer resistance to cis-
platin [38]. Thus, future studies, on patient cohorts
treated with neoadjuvant or palliative chemotherapy,
would be of interest to further assess the possible role of
IFITM1 as a predictive biomarker for response to
platinum-based chemotherapy.
A limitation of our study is the retrospective design.
However, all available surgically resected tumors were
included consecutively, which decreases the risk of se-
lection bias, and all clinical and histopathological data
have been thoroughly re-examined. Another possible
limitation is the use of the TMA technique, but since du-
plicate cores were obtained from different donor blocks,
the risk of sampling bias should be low. Moreover, analyz-
ing the data grouped by tumor location reduces the sam-
ple size and number of events and thus limits the
possibility to adjust for multiple possible confounders in
the Cox regression analyses. Due to the exploratory nature
of the study, our results should mainly be regarded as
hypothesis-generating, providing a basis for further ex-
ploration of IFITM1 as a biomarker in gastroesophageal
adenocarcinoma.
Conclusion
In summary, we have shown that the immunohistochemi-
cal expression of IFITM1 was elevated in gastroesophageal
adenocarcinoma and that it was associated with M0-
disease. In gastric cancer, IFITM1 had a positive impact
on TTR, whereas in esophageal cancer, data indicates an
adverse impact on survival, suggesting that the role of
IFITM1 may differ depending on the tumorigenic path-
way. The mechanistic basis for this observation merits
further study, and validatory studies on tumors from
additional patient cohorts are warranted.
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